Progress of anti-vascular endothelial growth factor therapy for ocular neovascular disease： benefits and challenges  

作　　者：Xu Jianjiang Li Yimin Hong Jiaxu 

机构地区：[1]Department of Ophthalmology, Eye, Ear, Nose, and Throat Hospital, School of Shanghai Medicine, Fudan University, Shanghai 200031, China

出　　处：《Chinese Medical Journal》2014年第8期1550-1557,共8页中华医学杂志（英文版）

基　　金：This work was supported by grants from the Key Chmc Medicine Research Program, the Ministry of Health, China （No. 201302015）, the National Science and Technology Research Program, the Ministry of Science and Technology, China （No. 2012BAI08B01）, the National Natural Science Foundation of China （Nos. 81170817, 81200658）, and the Scientific Research Program, Science and Technology Commission of Shanghai Municipality, Shanghai （Nos. 13441900900, 13430720400, 134119a8800, 13430710500）.

摘　　要：publication. Study selection Clinical trials and case studies presented at medical conferences and published in peer-reviewed literature in the past decade were reviewed. Results Anti-VEGF agents have manifested great potential and promising outcomes in treating ocular neovascularization, though some of them are still used as off-label drugs. Intravitrea~ injection of anti-VEGF agents could be accompanied by devastating ocular or systemic complications, and intimate monitoring in both adult and pediatric population are warranted. Future directions should be focused on carrying out more well-designed large-scale controlled trials, promoting sustained duration of action, developing safer and more efficient generation of anti-VEGF agents. Conclusions Anti-VEGF treatment has proved to be beneficial in treating both anterior and posterior neovascular ocular diseases. However, more safer and affordable antiangiogenic agencies and regimens are warranted to be explored.publication. Study selection Clinical trials and case studies presented at medical conferences and published in peer-reviewed literature in the past decade were reviewed. Results Anti-VEGF agents have manifested great potential and promising outcomes in treating ocular neovascularization, though some of them are still used as off-label drugs. Intravitrea~ injection of anti-VEGF agents could be accompanied by devastating ocular or systemic complications, and intimate monitoring in both adult and pediatric population are warranted. Future directions should be focused on carrying out more well-designed large-scale controlled trials, promoting sustained duration of action, developing safer and more efficient generation of anti-VEGF agents. Conclusions Anti-VEGF treatment has proved to be beneficial in treating both anterior and posterior neovascular ocular diseases. However, more safer and affordable antiangiogenic agencies and regimens are warranted to be explored.

关 键 词：vascular endothelial growth factor ＂ anti-vascular endothelial growth factor therapy ＂ ranibizumab BEVACIZUMAB AFLIBERCEPT PEGAPTANIB NEOVASCULARIZATION angiogenesis safety 

分 类 号：Q512.6[生物学—生物化学] S858.317.6[农业科学—临床兽医学]